Reliability and Validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 2, 2010, Pages 712-717

  Revicki, Dennis A ^a   Rentz, Anne M ^a   Harnam, Neesha ^a   Thomas, Vince S ^b   Lanzetta, Paolo ^b  

^a Center for Health Outcomes Research   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; EYE PAIN; FEMALE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE 25; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RETINA MACULA AGE RELATED DEGENERATION; SCORING SYSTEM; SHORT FORM 36; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL ANALOG SCALE; CONTRAST SENSITIVITY; DISABILITY; HEALTH SERVICES RESEARCH; HEALTH SURVEY; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; REPRODUCIBILITY; RETINA MACULA DEGENERATION; SICKNESS IMPACT PROFILE; UNITED STATES; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; CONTRAST SENSITIVITY; DISABILITY EVALUATION; FEMALE; HEALTH SERVICES RESEARCH; HEALTH SURVEYS; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; NATIONAL EYE INSTITUTE (U.S.); PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; UNITED STATES; VISUAL ACUITY;

EID: 77449123366     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3766     Document Type: Article

References (37)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11):844-851.
3. World Health Organization (WHO). Fact Sheet No. 282: Magnitude and causes of visual impairment. November 2004. Available at http://www.who.int/mediacentre/factsheets/fs282/en/print.html. Accessed January 19, 2007.
4. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study: AREDS Report No. 10. Arch Ophthalmol. Feb 2003;121(2): 211-217.
5. Cullinan TR. The Epidemiology of Visual Disability: Studies of Visually Disabled People in the Community. Canterbury, UK: University of Kent; Health Services Research Unit Report No. 28; 1977.
6. Genensky SM. Acuity measurements: do they indicate how well a partially sighted person functions or could function? Am J Optom Physiol Opt. 1976;53(12):809-812.
7. Hart PM, Chakravarthy U, Stevenson MR, Jamison JQ. A vision specific functional index for use in patients with age related macular degeneration. Br J Ophthalmol. 1999;83(10):1115-1120.
8. Mackenzie PJ, Chang TS, Scott IU, et al. Assessment of visionrelated function in patients with age-related macular degeneration. Ophthalmology. 2002;109(4):720-729.
9. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and healthrelated quality of life. Am J Ophthalmol. 1999;128(1):45-53.
10. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization-SST Report No. 1. Arch Ophthalmol. 2003;121(4):531-539.
11. Fine SL. Age-related macular degeneration 1969-2004: a 35-year personal perspective. Am J Ophthalmol. 2005;139(3):405-420.
12. Brody BL, Roch-Levecq AC, Gamst AC, et al. Self-management of age-related macular degeneration and quality of life: a randomized controlled trial. Arch Ophthalmol. 2002;120(11):1477-1483.
13. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-1058.
14. Bass EB, Marsh MJ, Mangione CM, et al. Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization: The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. Arch Ophthalmol. 2004;122(12):1856-1867.
15. Childs AL, Bressler NM, Bass EB, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings-SST report no. 14. Ophthalmology. 2004; 111(11):2007-2014.
16. Dong LM, Childs AL, Mangione CM, et al. Health-and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol. 2004;138(1):91-108.
17. Hawkins BS, Miskala PH, Bass EB, et al. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial-SST Report No. 10. Arch Ophthalmol. 2004;122(11): 1616-1628.
18. Miskala PH, Bressler NM, Meinert CL. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol. 2004;122(5):758-766.
19. Berdeaux GH, Nordmann JP, Colin E, Arnould B. Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol. 2005;139(2):271-279.
20. Maguire M. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology. 2004;111(7):1307-1316.
21. Matchar DB, Suner IJ, Samsa GP, et al. Measuring Quality of Life for Patients with Age-Related Macular Degeneration. Rockville, MD: Technology Assessment Program, Agency for Healthcare Research and Quality; February 2006.
22. Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116(11): 1496-1504.
23. Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14. Arch Ophthalmol. 2005;123(9):1207-1214.
24. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108(10):1893-1900; discussion 1900-1891.
25. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
26. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. Oct 5 2006;355(14):1419-1431.
27. Suner IJ, Kokame GT, Yu E, et al. NEI VFQ-25 is responsive to changes in visual acuity in neovascular AMD: results of validation studies using data from 2 phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629-35.
28. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460-1469.
29. Mangione CM. NEI VFQ-25 Scoring Algorithm. Rockville, MD: National Eye Institute; 2000.
30. Ware JE, Snow KK, Kosinski MK, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
31. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40-66.
32. Ware JE, Kosinski MK, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, New England Medical Center; 1994.
33. Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2003.
34. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91-96.
35. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vision Sci. 1988;2(3):187-199.
36. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
37. Hays RD, Revicki DA. Reliability and validity (including responsiveness). In: Fayers P, Hays RD, eds. Assessing Quality of Life in Clinical Trials: Methods and Practice. 2nd ed. Oxford, UK: Oxford University Press; 2005:25-39.